Mavacamten Treatment Associated With Improved Diastolic Function, Remodeling Markers - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Mavacamten Treatment Associated With Improved Diastolic Function, Remodeling Markers

Real-world follow-up data from 465 patients add to evidence from earlier randomized trials.

  • By

  • Kathryn Wighton

  • June 27, 2026

  • 3 min

Share

Clinical Scorecard: Mavacamten Treatment Associated With Improved Diastolic Function, Remodeling Markers

At a Glance

CategoryDetail
ConditionSymptomatic Obstructive Hypertrophic Cardiomyopathy
Key MechanismsSelective cardiac-specific myosin inhibitor
Target PopulationAdults with symptomatic obstructive hypertrophic cardiomyopathy
Care SettingRetrospective analysis of patient-level data across multiple sites

Key Highlights

  • Statistically significant improvements in diastolic function and cardiac remodeling markers at 18 months
  • Increased medial e′ velocity from 0.05 m/s to 0.06 m/s
  • Decreased average E/e′ ratio from 17.4 to 14.2
  • Decreased left ventricular wall thickness (LVWT) from 18.5 mm to 17.6 mm
  • No new safety signals reported

Guideline-Based Recommendations

Diagnosis

  • Assessment of echocardiographic markers for diagnosis of obstructive hypertrophic cardiomyopathy

Management

  • Mavacamten treatment in accordance with US Prescribing Information

Monitoring & Follow-up

  • Regular echocardiographic assessments at baseline and follow-up

Risks

  • Retrospective, uncontrolled analysis limits interpretation of safety findings

Patient & Prescribing Data

465 patients with symptomatic obstructive hypertrophic cardiomyopathy

Mavacamten showed improvements in diastolic function and cardiac remodeling markers

Clinical Best Practices

  • Monitor echocardiographic parameters regularly in treated patients
  • Consider patient selection and concurrent management in interpreting treatment effects

Related Resources & Content

Original Source(s)

Mavacamten Treatment Associated With Improved Diastolic Function, Remodeling Markers

  • by Kathryn Wighton

  • June 27, 2026

Related Content

Curtobacterium oceansedimentum Infective Endocarditis: A Plant-Associated Pathogen Causing Acute Heart Failure From Severe Valvular Dysfunction

  • October 20, 2026

FDA adds generic valganciclovir oral solution

 The new option is indicated for CMV prophylaxis in pediatric kidney and heart transplant recipients, as well as adult CMV retinitis and transplant prophylaxis.

Mortality score may refine heart allocation

A laboratory- and device-based model outperformed the current 6-status system in predicting short-term mortality among heart transplant candidates.